ArticleGlobal health research and policy2025
Access to antimalarial drugs in the Asia-Pacific region during health emergency: a multinational cross-sectional investigation between 2020 and 2022.
Article in Global health research and policy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMalaria elimination in the Asia-Pacific region has stalled in recent years, partially due to disrupted access to antimalarial drugs during public health emergencies. This study aims to explore the access to antimalarial drugs and its contextual factors in health emergencies based on investigation into six Asia-Pacific countries during the COVID-19, including Bangladesh, India, Indonesia, Pakistan, Thailand and Viet Nam.
methodsWe extracted the quarterly data for 37 antimalarial drugs using the IQVIA database from the first quarter in 2020 to the second quarter in 2022. We used standard units (SU) sold per 1000 incident cases and US dollars per 1000 incident cases to evaluate consumption (accessibility). Changes in consumption were estimated using compound annual growth rate (CAGR). Associations between consumption and country's socioeconomic, health performance and product supplier indicators were measured using least squares (pooled) panel data regression model.
resultsAvailable antimalarial drugs ranged from 31 in India, and 6 in Bangladesh and Viet Nam. The predominant medicine category in all six countries was quinine and other quinoline derivatives. The highest level of average consumption per 1000 incident cases was observed in Viet Nam (2004141.9 SU per 1000 incident cases). The country presenting the lowest level of accessibility was Indonesia (3668 SU per 1000 incident cases). Between 2020 and 2022, all countries except Viet Nam presented a decreased consumption per 1000 incident cases, with CAGRs being respectively - 15.11% in Bangladesh, - 3.66% in India, - 23.56% in Indonesia, - 13.28% in Pakistan and - 12.07% in Thailand. Increased Log consumption per 1000 incident cases was associated with higher proportion of health expenditure out of total government expenditure (coefficient 1.84, 95% confidence interval 0.47-3.21) and higher proportion of local supply (coefficient 0.43, 95% confidence interval 0.06-0.80).
conclusionsThere has been a disruption in the access to antimalarial drugs during the COVID-19 pandemic in the Asia-Pacific region, and the predominant available medicines were those with documented resistance. Greater priority should be given to drug innovation aimed at improving availability, along with strengthening health systems and local production to maintain accessibility to these drugs, especially during health emergencies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.